WS
ACHN

Wedbush Securities’s Achillion Pharmaceuticals ACHN Stock Holding History

Wedbush Securities’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-12,000
Closed -$35K – 915
2017
Q4 		$35K Buy
+12,000
New +$43.6K ﹤0.01% 832

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wedbush Securities's ACHN Position: Q1 2018 in Review

Wedbush Securities sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 12,000 shares — an estimated $35K sold.

Wedbush Securities first reported a position in ACHN in Q4 2017 and held it in 1 quarter. The position peaked at $35K in Q4 2017. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

  • Wedbush Securities reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Wedbush Securities sold 12,000 Achillion Pharmaceuticals shares in Q1 2018, an estimated $35K.
  • Wedbush Securities first reported a position in Achillion Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Wedbush Securities's Achillion Pharmaceuticals position peaked at $35K in Q4 2017.
  • 127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on Wedbush Securities's 13F filing for Q1 2018, filed 1 May 2018.